Screening people with diabetes for eye damage using artificial intelligence
Studies an AI tool to screen adults with diabetes for diabetic retinopathy, an eye disease.
Plain-language title generated from the registry record
Registry title: The Diabetic Retinopathy Screening, Prevention and Control Program
Key facts
- Where
- Shanghai, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes. Non-diabetic patients and healthy volunteers from other medical centres are also invited.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diabetes: type 2 diabetes by the 1999 WHO criteria, and also type 1, single-gene mutation diabetes, or diabetes caused by pancreas damage, Cushing's syndrome, thyroid problems or acromegaly
Main reasons for not taking part
- History of drug abuse
- Active sexually transmitted diseases such as AIDS and syphilis
- Active infectious diseases such as viral hepatitis and tuberculosis
- Any condition that the investigator thinks makes joining the study unwise
Read by machine on 12 November 2026.
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Guang Ning, ProfessorTaking people
- Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Guang Ning, MD,PHDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT04240652
- Record updated
- 5 February 2020
- Original description
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.Read full original descriptionShow less
The Diabetic Retinopathy Screening, Prevention and Control Program
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.
Inclusion: Meet the diagnostic criteria for type 2 diabetes according to the World Health Organization (WHO) in 1999; Type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, Cushing's syndrome, thyroid dysfunction, or acromegaly; Subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study.
Exclusion: Those who have a history of drug abuse; Sexually transmitted diseases such as AIDS and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase; Any condition that the investigator think that the subject is not suitable for participating in the study; For detailed In-/Ex-clusion criteria please see the study protocol.